Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study
Loreta A. Kondili(Istituto Superiore di Sanità), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Marco Massari(Azienda Sanitaria Unità Locale di Reggio Emilia), Alfredo Di Leo(University Gastroenterology), Elena Danieli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Roberto Gulminetti(University of Pavia), Alberto Zanetto(University of Padua), Romina Corsini(Azienda Ospedaliera S.Maria), Francesco Paolo Russo(University of Padua), Anna Linda Zignego(University of Florence), Monica Monti(University of Florence), Alessandro Soria(University of Milano-Bicocca), Andrea Iannone(University of Bari Aldo Moro), Roberto Filomia(University of Messina), Andrea Gori(University of Milan), Giovanni Raimondo(University of Messina), Pierluigi Toniutto(University of Udine), Alberto Gatti Comini(University of Pavia), Stefano Vella, Maurizia Rossana Brunetto(University of Pisa), Donatella Ieluzzi(University of Verona), Maria Grazia Rumi(University of Milan), Giuseppina Brancaccio, Liliana Elena Weimer(Istituto Superiore di Sanità), Maria Giovanna Quaranta(Istituto Superiore di Sanità), D. Dissegna(University of Udine), Giovanni Battista Gaeta
Cited by 5
Related Papers
Treatment for Adult HIV Infection
|JAMA|2006|1k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
Antiretroviral Therapy for HIV Infection in 1998
|JAMA|1998|1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Treatment for Adult HIV Infection
|JAMA|2004|737